Randomized phase III study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401‐ MITSUBA)

BACKGROUND: Gemcitabine/cisplatin (GC) combination therapy has been the standard palliative chemotherapy for patients with advanced biliary tract cancer (BTC). No randomized clinical trials have been able to demonstrate the survival benefit over GC during the past decade. In our previous phase II tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ioka, Tatsuya, Kanai, Masashi, Kobayashi, Shogo, Sakai, Daisuke, Eguchi, Hidetoshi, Baba, Hideo, Seo, Satoru, Taketomi, Akinobu, Takayama, Tadatoshi, Yamaue, Hiroki, Takahashi, Masahiro, Sho, Masayuki, Kamei, Keiko, Fujimoto, Jiro, Toyoda, Masanori, Shimizu, Junzo, Goto, Takuma, Shindo, Yoshitaro, Yoshimura, Kenichi, Hatano, Etsuro, Nagano, Hiroaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086809/
https://www.ncbi.nlm.nih.gov/pubmed/35900311
http://dx.doi.org/10.1002/jhbp.1219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086809/
https://www.ncbi.nlm.nih.gov/pubmed/35900311
http://dx.doi.org/10.1002/jhbp.1219

Ejemplares similares